Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines.
Mariangela TamburelloAndrea AbateElisa RossiniRam Manohar BasnetDaniela ZizioliDeborah CosentiniConstanze HantelMarta LaganàGuido Alberto Massimo TiberioSalvatore GrisantiMaurizio MemoAlfredo BerrutiSandra SigalaPublished in: International journal of molecular sciences (2023)
Our results give support to the role of progesterone in ACC. The involvement of its analog (megestrol acetate) in reducing ACC progression in ACC patients undergoing EDP-M therapy is now under investigation in the PESETA phase II clinical study.